Alzheimer's Disease Neuroimaging Initiative multisite study
Alzheimer's Disease Neuroimaging Initiative (Project)
Alzheimer's Disease Neuroimaging Initiative
VIAF ID: 166145365 (Corporate)
Permalink: http://viaf.org/viaf/166145365
Preferred Forms
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| Callosal thickness profiles for prognosticating conversion from mild cognitive impairment to Alzheimer's disease: A classification approach. |
|
| Future opportunities to leverage the Alzheimer's Disease Neuroimaging Initiative, c2011: |
|
| Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study |
|
| Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries |
|
| Modeling Alzheimer's disease cognitive scores using multi-task sparse group lasso. |
|
| Modeling clustered activity increase in amyloid-beta positron emission tomographic images with statistical descriptors |
|
| Modeling disease progression via multi-task learning |
|
| Modeling Multi-View Dependence in Bayesian Networks for Alzheimer's Disease Detection |
|
| Modeling transcranial electrical stimulation in the aging brain |
|
| Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease |
|
| Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume |
|
| Modulation of glucose metabolism and metabolic connectivity by β-amyloid. |
|
| Molecular properties underlying regional vulnerability to Alzheimer's disease pathology |
|
| Monotonic Gaussian Process for spatio-temporal disease progression modeling in brain imaging data |
|
| Morphometric network differences in ageing versus Alzheimer's disease dementia |
|
| Morphometricity as a measure of the neuroanatomical signature of a trait |
|
| MRI and cognitive scores complement each other to accurately predict Alzheimer's dementia 2 to 7 years before clinical onset |
|
| MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations |
|
| MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials |
|
| MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults |
|
| MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures |
|
| Multi-Channel neurodegenerative pattern analysis and its application in Alzheimer's disease characterization |
|
| Predicting the course of Alzheimer’s progression |
|
| Quantification of structural brain connectivity via a conductance model |
|
| Quantifying anatomical shape variations in neurological disorders |
|
| Quantifying brain metabolism from FDG-PET images into a probability of Alzheimer's dementia score |
|
| Quantifying Neurodegenerative Progression With DeepSymNet, an End-to-End Data-Driven Approach |
|
| Quantifying the pathophysiological timeline of Alzheimer's disease |
|
| Quantifying uncertainty in brain-predicted age using scalar-on-image quantile regression |
|
| Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. |
|
| Quantitative assessment of corpus callosum morphology in periventricular nodular heterotopia |
|
| Quantitative assessment of field strength, total intracranial volume, sex, and age effects on the goodness of harmonization for volumetric analysis on the ADNI database |
|
| Quantitative trait loci identification for brain endophenotypes via new additive model with random networks |
|
| QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy |
|
| Random forest-based similarity measures for multi-modal classification of Alzheimer's disease |
|
| Random forest prediction of Alzheimer's disease using pairwise selection from time series data |
|
| Random forests on Hadoop for genome-wide association studies of multivariate neuroimaging phenotypes |
|
| Rapid fully automatic segmentation of subcortical brain structures by shape-constrained surface adaptation. |
|
| Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials |
|
| Rates of decline in Alzheimer disease decrease with age. |
|
| Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials |
|
| Reconstructing subject-specific effect maps |
|
| Reduced brain amyloid burden in elderly patients with narcolepsy type 1 |
|
| Reducing post-lumbar puncture headaches with small bore atraumatic needles |
|
| Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden |
|
| Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment |
|
| Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer's disease-associated genes: DTNB and DLG2 |
|
| Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease |
|
| Regional Amyloid Accumulation and White Matter Integrity in Cognitively Normal Individuals |
|
| Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume |
|
| Regional brain hypometabolism is unrelated to regional amyloid plaque burden |
|
| Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. |
|
| Regional flux analysis for discovering and quantifying anatomical changes: An application to the brain morphometry in Alzheimer's disease. |
|
| Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline |
|
| Regional imaging genetic enrichment analysis |
|
| Regional rates of neocortical atrophy from normal aging to early Alzheimer disease |
|
| Regional segmentation strategy for DTI analysis of human corpus callosum indicates motor function deficit in mild cognitive impairment |
|
| Registration of images with varying topology using embedded maps |
|
| Regularized Bagged Canonical Component Analysis for Multiclass Learning in Brain Imaging |
|
| Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study |
|
| Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease |
|
| Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: an in vivo positron emission tomography study |
|
| Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI |
|
| Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults |
|
| Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease. |
|
| Relationships among Cortical Glutathione Levels, Brain Amyloidosis, and Memory in Healthy Older Adults Investigated In Vivo with 1H-MRS and Pittsburgh Compound-B PET. |
|
| Relationships between biomarkers in aging and dementia |
|
| Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease |
|
| Relative contributions of biomarkers in Alzheimer's disease |
|
| Relevant feature set estimation with a knock-out strategy and random forests |
|
| Reliable change in neuropsychological test scores is associated with brain atrophy in older adults |
|
| Removing inter-subject technical variability in magnetic resonance imaging studies |
|
| Renal function affects hippocampal volume and cognition: The role of vascular burden and amyloid deposition |
|
| Reproducibility of Deep Gray Matter Atrophy Rate Measurement in a Large Multicenter Dataset. |
|
| Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data |
|
